Key facts today
19.457 BRL
86.65 B BRL
249.17 B BRL
3.15 B
About NOVO NORDISK B A/S
Sector
CEO
Lars Fruergaard Jørgensen
Headquarters
Bagsværd
Website
Founded
1931
ISIN
BRN1VOBDR005
FIGI
BBG00XX9KCX6
Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.
Double bottom in consolidation zonePrice creates a double bottom inside orange consolidation zone
Also daily sma200 (blu line) act as a strong support
I think everything is ready for a reversal
I am cautiously calling the bottom on NVOIt might be a bit early to call this a bottom, especially given the unpredictable market, but I’m noticing a few key signals aligning:
The 8/21 curl following a double bottom
A break above the 50-day SMA occurring on a red day like today
Momentum shifting positive and being released from a squ
Opening (IRA): NVO March 28th 76 Covered Call... for a 74.50 debit.
Comments: Taking what amounts to a modest directional shot with a break even below the 52-week lows, selling the -75 delta call against shares to emulate the delta metrics of a 25 delta short put, but with the built-in defense of the short call.
Metrics:
Buying Power Effec
Finally a stock I like...this one is a real dealFinally, an investment idea! (after how much doom and gloom?) — Novo Nordisk.
You will all be familiar with Ozempic, the Danish company’s flagship product and the reason so many celebrities, influencers, b listers and regular schmegular Americans are suddenly skinny. I ignored the stock for most of
Buy Opportunity for NVONovo Nordisk A/S – Financial Summary and Outlook (2024):
Sales Growth: Up 23% in Danish kroner (DKK 204.7 billion) and 24% at constant exchange rates (CER).
Operating Profit: Increased by 21% (DKK 91.6 billion).
Net Profit: Rose 18% to DKK 72.8 billion.
Product Highlights:
Wegovy (Obesity)
BUY NOVO!!Easy 70% to be gained on this stock. Looks like this current level is where we are going to bottom out and begin a bullish phase.
$NVO more pain ahead! Headed down to $46-55 - NYSE:NVO was one of the hottest stocks of 2024 is now facing immense challenges by other healthcare companies in weight loss drug.
- With weak results, it sets up for disappointment for 1-2 quarters. Quick turnaround in experiments isn't feasible and would need considerable time to show promis
Buy signal for NVOGood earnings aside, we got a buy signal on the weekly chart so we are looking the first target being the weekly 21ema, which is currently sitting at around $100
Novo is going to 480. Wait for it!OMXCOP:NOVO_B Is declining to 480. I think that will be a good price to buy. It has a lot of bad news ahead. But this bad news is not that bad. So see you at 480!
See all ideas
Displays a symbol's price movements over previous years to identify recurring trends.
Curated watchlists where N1VO34 is featured.
